Overview

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Johns Hopkins University
University of Nebraska